Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: Implications for multiple sclerosis clinical trials

Multiple Sclerosis Journal

Volumn 18, Issue 9, 2012, Pages 1320-1325

  Benedict, Ralph H B ^a   Smerbeck, Audrey ^a   Parikh, Rajavi ^a   Rodgers, Jonathan ^a   Cadavid, Diego ^b   Erlanger, David ^c  

^a BUFFALO GENERAL HOSPITAL   (United States)

^b BIOGEN   (United States)

^c Memen Pharmaceuticals LLC   (United States)

Author keywords

cognition; Multiple sclerosis; outcome measurement; symptomatic treatment

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL RESEARCH; METHODOLOGY; MULTIPLE SCLEROSIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RELIABILITY; SYMBOL DIGIT MODALITIES TEST; TEST RETEST RELIABILITY;

EID: 84864810149     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511435717     Document Type: Article

References (48)

1. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011 ; 10: 332-342
2. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008 ; 7: 1139-1151
3. Rovaris M, Riccitelli G, Judica E, et al. Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology. 2008 ; 71: 1521-1526
4. Goverover Y, Chiaravalloti N, DeLuca J. Self-generation to improve learning and memory of functional activities in persons with multiple sclerosis: meal preparation and managing finances. Arch Phy Med Rehabil. 2008 ; 89: 1514-1521
5. Benedict RHB, Wahlig E, Bakshi R, et al. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005 ;: 29-34
6. Gronwall DMA. Paced auditory serial addition task: A measure of recovery from concussion. Percept Motor Skills. 1977 ; 44: 367-373
7. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology. 2001 ; 56: 1324-1330
8. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006 ; 67: 1242-1249
9. Aupperle RL, Beatty WW, Shelton Fde N, Gontkovsky ST. Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult Scler. 2002 ; 8: 382-389
10. Smith A Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services ; 1982:
11. Rao SM A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. National Multiple Sclerosis Society ; 1991:
12. Benedict RHB, Bakshi R, Simon JH, Priore R, Miller C, Munschauer F. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2002 ; 14: 44-51
13. Benedict RHB, Priore RL, Miller C, Munschauer F, Jacobs L. Personality disorder in multiple sclerosis correlates with cognitive impairment. J Neuropsychiatry Clin Neurosci. 2001 ; 13: 70-76
14. Simon JH, Jacobs LD, Campion M, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology. 1999 ; 53: 139-148
15. Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain. 1999 ; 122: 1341-1348
16. Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 ; 76: 519-526
17. Huijbregts SC, Kalkers NF, de Sonneville LM, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004 ; 63: 335-339
18. Nocentini U, Giordano A, Di Vincenzo S, et al. The Symbol Digit Modalities Test - Oral version: Italian normative data. Funct Neurol. 2006 ; 21: 93-96
19. Nocentini U, Pasqualetti P, Bonavita S, et al. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006 ; 12: 77-87
20. Parmenter BA, Testa SM, Schretlen DJ, et al. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2010 ; 16: 6-16
21. Strober L, Englert J, Munschauer F, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler. 2009 ; 15: 1077-1084
22. Parmenter BA, Weinstock-Guttman B, Garg N, et al. Screening for cognitive impairment in MS using the Symbol Digit Modalities Test. Mult Scler. 2007 ; 13: 52-57
23. Benedict RHB, Bruce JM, Dwyer MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunciton in multiple sclerosis. Arch Neurol. 2006 ; 63: 1301-1306
24. Benedict RHB, Cookfair D, Gavett R, et al. Validity of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006 ; 12: 549-558
25. Bermel RA, Sharma J, Tjoa CW, et al. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci. 2003 ; 208: 57-65
26. Christodoulou C, Krupp LB, Liang Z, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology. 2003 ; 60: 1793-1798
27. Benedict RH, Ramasamy D, Munschauer F, et al. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry. 2009 ; 80: 201-206
28. Tekok-Kilic A, Benedict RHB, Weinstock-Guttman B, et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage. 2007 ; 36: 1294-1300
29. Benedict RHB, Bruce J, Dwyer MG, et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler. 2007 ; 13: 722-730
30. Benedict RHB, Zivadinov R, Carone D, et al. Regional Lobar Atrophy Predicts Memory Impairment in Multiple Sclerosis. Am J Neuroradiol. 2005 ; 26: 1824-1831
31. Benedict RHB, Carone D, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging. 2004 ; 14 (3 Suppl). 36S - 45S
32. Benedict RHB, Weinstock-Guttman B, Fishman I, et al. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004 ; 61: 226-230
33. Brochet B, Deloire MS, Bonnet M, et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler. 2008 ; 14: 1242-1249
34. Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASATwith the Symbol Digit Modalities Test. Mult Scler. 2010 ; 16: 228-237
35. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999 ; 5: 244-250
36. Benedict RHB. Effects of using same vs. alternate form memory tests in short-interval, repeated assessment in multiple sclerosis. J Int Neuropsychol Soc. 2005 ; 11: 727-736
37. Benedict RHB, Duquin JA, Jurgensen S, et al. Repeated Assessment of Neuropsychological Deficits in Multiple Sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler. 2008 ;: 940-946
38. Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010 ; 16: 228-237
39. Morrow SA, O'Connor PW, Polman CH, et al. Evaluation of the Symbol Digit Modalities Test (SDMT) and MS Neuropsychological Screening Questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010 ; 16: 1385-1392
40. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler. 2001 ; 7: 263-267
41. Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991 ; 41: 692-696
42. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral and biomedical sciences. Behav Res Methods. 2007 ; 39: 175-191
43. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improves memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004 ; 63: 1579-1585
44. Sumowski JF, Chiaravalloti N, Erlanger D, et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler. 2011 ; 17: 1141-1145
45. Morrow SA, Kaushik T, Zarevics P, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009 ; 256: 1095-1102
46. Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011 ; 76: 1500-1507
47. Morrow SA, Jurgensen S, Forrestal F, et al. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. J Neurol. 2011 ; 258: 1603-1608
48. Morrow SA, Drake AS, Zivadinov R, et al. Predicting loss of employment over three years in multiple sclerosis: Clinically meaningful cognitive decline. Clin Neuropsychol. 2010 ; 24: 1131-1145